Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

LQLing QinALAijun LiaoCSChunyan Sun

Discussion

Loading...

Member takes

Overview

Open-label trial demonstrated significant anti-tumor activity in relapsed/refractory multiple myeloma, indicating a promising safety profile.

Key Points

  • To evaluate the efficacy and safety of LBL-034, a bispecific antibody, in patients with relapsed/refractory multiple myeloma.
  • Phase I/II, open-label, multicenter trial
  • Eligible patients had received ≥3 prior therapies
  • Dose escalation from 10 to 1200 μg/kg
  • Tumor responses assessed per IMWG criteria
  • Safety measured via adverse events grading
  • Overall response rate was 70.9% among evaluable patients
  • Minimal residual disease negativity achieved in 84.2% of MRD-evaluable patients
  • Cytokine release syndrome occurred in 73.2% of patients, mainly manageable
  • Adverse events predominantly grade 1 or 2; severe events reported in 83.9% of patients

Cite This Study

Qin et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d048https://doi.org/10.1182/blood-2025-91
View Full Paper
Ask AI
Bookmark
Share